For Healthcare Professionals

Patient Assistance

EMD Serono makes fertility treatment more affordable for your patients. Your patients can start saving now.

EMD Serono offers your patients infertility support resources, treatment information and patient savings programs

  • For many patients, cost can be a determining factor in embarking on and continuing fertility treatment, and cost is the primary reason patients stop fertility treatment.
  • Considering that a U.S. fertility patient could receive 3 to 4 cycles of in vitro fertilization (IVF) per year, assistance is key.23

As you are caring for your patients, remember that EMD Serono provides several financial assistance programs to help your patients reach their goals.

Learn more about patient savings programs below.

Eligible patients with private insurance can save up to $250* on out-of-pocket costs by using the Co-Pay Savings Card.

To help your patients save up to $250* per prescription:

  • Prescribe Gonal-f® (follitropin alfa for injection), Ovidrel (choriogonadotropin alfa injection) and/or Cetrotide (cetrorelix acetate for injection)
  • A valid Gonal-f® prescription is required in order to receive Co-Pay assistance for Ovidrel (choriogonadotropin alfa injection) and Cetrotide (cetrorelix acetate for injection)
  • Ensure that the patient has the Co-Pay Savings Card
  • Or, fax card with Rx to pharmacy
  • Or, enter the BIN, GROUP and ID Numbers into ePrescribe

Request a Co-Pay Card Now


*Program Details:

  • Patients must have a prescription drug benefit that covers Gonal-f®, Ovidrel and/or Cetrotide and a valid prescription for Gonal-f®, Ovidrel and/or Cetrotide. A valid Gonal-f® prescription is required in order to receive Co-Pay assistance for Ovidrel and Cetrotide
  • Patients cannot combine this card with any other rebate, coupon, free trial, or similar offer
  • Save up to $200 off Gonal-f, up to $25 off of Ovidrel and up to $25 off of Cetrotide
  • Patient should keep card for repeated use
  • Offer is valid for the duration of the program, unless earlier terminated by EMD Serono
  • EMD Serono reserves the right to rescind, revoke, terminate, or amend the Co-Pay Savings Card at any time without notice

Covers the following products:

  • Gonal-f® RFF Redi-jectTM 300 IU (follitropin alfa injection)
  • Gonal-f® RFF Redi-jectTM 450 IU (follitropin alfa injection)
  • Gonal-f® RFF Redi-jectTM 900 IU (follitropin alfa injection)
  • Gonal-f® Multi-Dose 450 IU (follitropin alfa for injection)
  • Gonal-f® Multi-Dose 1050 IU (follitropin alfa for injection)
  • Gonal-f® RFF 75 IU, single vial pack (follitropin alfa for injection)
  • Gonal-f® RFF 75 IU, 10 vial pack (follitropin alfa for injection)
  • Cetrotide (cetrorelix acetate for injection)
  • Ovidrel PreFilled Syringe (choriogonadotropin alfa injection)

Not valid for cash paying patients

Offer not valid for prescriptions that may be reimbursed under federal or state healthcare programs, including Medicaid, Medicare, or any other similar programs, including any state medical pharmaceutical assistance program

Void in states where rebates are prohibited by law, taxed, or otherwise restricted

 

IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF Gonal-f® RFF Redi-ject™ (follitropin alfa injection)

Indications and Usage: 

  • Induction of ovulation (OI) and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure
  • Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle.
    • Prior to treatment, complete an evaluation of female and male partners to determine infertility diagnosis. Primary ovarian failure and potential pregnancy should be excluded.

Contraindications:

  • hypersensitivity to rhFSH preparations or excipients
  • high levels of FSH indicating primary gonadal failure
  • pregnancy (Pregnancy Category X)
  • uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
  • sex hormone dependent tumors of the reproductive tract and accessory organs
  • tumors of pituitary gland or hypothalamus
  • abnormal uterine bleeding
  • ovarian cyst or enlargement of undetermined origin, not due to polycystic ovary syndrome.

Warnings and Precautions:

  • For use by physicians specializing in fertility treatment or reproductive health and only when appropriate monitoring facilities are available.
  • Gonal-f® RFF Redi-ject™ is a potent gonadotropin.  The lowest effective dose should be used given risk of abnormal ovarian enlargement and Ovarian Hyperstimulation Syndrome (OHSS).  Ultrasound monitoring of ovarian response and/or measurement of estradiol levels are important to minimize risks.  If symptoms of OHSS (severe pelvic or abdominal pain and distension, nausea, vomiting, diarrhea, severe ovarian enlargement, weight gain, dyspnea, oliguria) develop, all gondotropin treatment should be stopped, hCG should be withheld, and intercourse should be prohibited.  OHSS can be severe and requires hospitalization and treatment of fluid and electrolyte imbalances.  OHSS may occur with or without pregnancy.  Women should be assessed for the development of OHSS for at least two weeks after hCG administration.
  • Serious systemic hypersensitivity reactions, including anaphylaxis, have been reported in the postmarketing experience.  Symptoms have included dyspnea, facial edema, pruritis, and urticaria.  If an anaphylactic or other serious allergic reaction occurs, initiate appropriate therapy including supportive measures if cardiovascular instability and/or respiratory compromise occur, and discontinue further use.
  • Thromboembolic events both in association with, and separate from OHSS have been reported in women treated with gonadotropins.  Women with generally recognized risk factors for thrombosis, such as personal or family history, severe obesity, or thrombophilia, may have an increased risk of venous or arterial thromboembolic events, during or following treatment with gonadotropins.  Sequelae of such reactions have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb and rarely in myocardial infarctions.  In rare cases, pulmonary complications and/or thromboembolic reactions have resulted in death.  In women with recognized risk factors, the benefits of OI and ART need to be weighed against the risks.
  • Serious pulmonary conditions (e.g., atelectasis, acute respiratory distress syndrome and exacerbation of asthma) have been reported in women treated with gonadotropins.
  • Ovarian torsion has been reported after treatment with gonadotropins.  This may be related to OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries.  Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion.
  • The couple should be advised of the potential risk of multi-fetal gestation and birth before beginning therapy.  During clinical trials, multiple births occurred in 20% of live births in women receiving therapy for ovulation induction and 35.1 % of live births in women undergoing ART.
  • The incidence of congenital malformations after some ART [specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI.
  • Since women undergoing ART often have tubal abnormalities, the incidence of ectopic pregnancy may be increased
  • The incidence of spontaneous abortion may be increased.  However, causality has not been established.  This may be a factor of the underlying infertility.
  • Both benign and malignant ovarian neoplasms have been infrequently reported; causality has not been established.
  • Both ultrasound and serum estradiol measurement should be used to monitor follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement, and minimizing the risk of the OHSS and multiple gestation.

Adverse Reactions:

The most common adverse reactions (≥5%) in OI include: headache, abdominal pain, and ovarian hyperstimulation.  The most common adverse reactions (≥5%) in ART include: abdominal pain, nausea, abdominal enlargement, headache, and injection site reactions (pain, bruising).

Patient Counseling:

In addition to advising patients about the proper use of treatment, the duration and necessity of monitoring, handling of missed doses, OHSS, and multi-fetal gestation and birth, patients should be advised to review the Patient Information Leaflet which contains risk information, follow the Instructions for Use for the Gonal-f® RFF Redi-ject™, not share the device or reuse needles, and to ask their HCP about questions.

HCP should refer to the full Prescribing Information for full disclosure.

*revised formulation female


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF Gonal-f® (follitropin alfa for injection):

Indication: 

For women, Gonal-f® (follitropin alfa for injection) and Gonal-f® RFF* (follitropin alfa injection) are indicated for 1) the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure and 2) for the development of multiple follicles in the ovulatory patient participating in an ART program. 

Gonal-f® is also indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.

Important Risk Information:  

These products should only be prescribed by physicians specializing in fertility or reproductive health.  Use of Gonal-f® or Gonal-f® RFF by women can result in multiple births.  Gonal-f® and Gonal-f® RFF  are potent gonadotropins capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary complications.  Gonal-f® and Gonal-f® RFF are contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor.  Additionally, Gonal-f® and Gonal-f® RFF  should not be given to women with abnormal bleeding,  presence or enlargement of an ovarian cyst of undetermined origin, or who are pregnant or nursing.  The most common side effects reported in women using Gonal-f® and Gonal-f® RFF include headache, abdominal pain, enlarged abdomen, ovarian cysts, nausea, and upper respiratory infections.  Men using Gonal-f® have commonly reported acne, breast pain and growth, fatigue.  Injection site reactions have been reported.

*revised formulation female


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF OVIDREL® PREFILLED SYRINGE (choriogonadotropin alfa injection):

Ovidrel® PreFilled Syringe (choriogonadotropin alfa for injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as in vitro fertilization (IVF) and embryo transfer.  Ovidrel® PreFilled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure.  Ovidrel®  PreFilled Syringe should only be used by physicians who are thoroughly familiar with infertility problems and their management.  

Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without blood vessel or lung problems. Ovidrel® PreFilled Syringe is contraindicated in women who exhibit prior sensitivity to hCG preparations or their ingredients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Women who are nursing should also not use Ovidrel® PreFilled Syringe The most common side effects in women using Ovidrel® PreFilled Syringe include abdominal pain, injection site reactions, nausea and vomiting.  Reports of multiple births have been associated with Ovidrel® PreFilled Syringe treatment.


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF CETROTIDE® (cetrorelix acetate for injection):

Cetrotide® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Cetrotide® should be prescribed by physicians who are experienced in fertility treatment.

Cetrotide® is contraindicated in women who exhibit hypersensitivity to cetrorelix acetate, mannitol or medicines similar to Cetrotide®, who exhibit prior hypersensitivity to GnRH or any other GnRH analogs, or who are pregnant, are  breast-feeding or have severe kidney disease. Ovarian Hyperstimulation Syndrome (OHSS), with or without blood vessel or lung problems , can occur with the use of fertility drugs. Mild and short lasting injection reactions like reddening, itching and swelling at the injection sites may occur. Nausea and headache have also been reported.


© 2014 EMD Serono, Inc. and its affiliates.

This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

New Tiered Approach: Eligible Patients may save either 50% or 75%

                                                    

  • Committed to helping eligible patients overcome financial barriers, the Compassionate Care Program may provide significant savings on EMD Serono medications for uninsured, income-eligible patients.
  • Eligibility is based on qualifying annual household gross income and first-time participation in the Compassionate Care program

 

More patients can now save on Gonal-f® (follitropin alfa for injection), Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection), or Cetrotide® (cetrorelix acetate for injection).

Eligible patients can use the Compassionate Care Program for multiple cycles within each year*

*Patients must reapply each year.


Enrollment Process

Prescribers:

Invite uninsured patients to apply for Compassionate Care benefits by clicking here or calling (855) 541-5926, upon prescribing a qualifying EMD Serono product:

  • Gonal-f® (follitropin alfa for injection),
  • Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection),
  • Cetrotide® (cetrorelix acetate for injection).

Patients:

  1. Click here or call (855) 541-5926 to obtain the Compassionate Care enrollment forms.
  2. Complete the Compassionate Care enrollment forms, patient authorization forms, and include the required income verification documents. Patient’s can submit all of these documents via Mail, Fax or Email:
  3. Eligible patients will receive an e-mail and subsequent mailing with their Compassionate Care redemption card
  4. Present card along with prescription to a participating pharmacy and receive a discount off the cash price available at that pharmacy for the select medications

Compassionate Care Program Details

Benefit for patients with demonstrated financial need and a valid prescription for Gonal-f® (follitropin alfa for injection), Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection), or Cetrotide® (cetrorelix acetate for injection)

  • Benefit is available at participating pharmacies only
  • Patients can save 50% or 75% off the available self-pay price at the participating pharmacy
  • The Compassionate Care Program is available for multiple cycles within each year.
  • Patients must reapply each year
  • Patients may not combine this card with any rebate, coupon, free trial, or similar offer
  • Patients must present a valid prescription for an eligible drug at a participating pharmacy
  • EMD Serono reserves the right to rescind, revoke, terminate, or amend the Compassionate Care Card at any time without notice

Covers the following products:

  • Gonal-f® RFF* Redi-jectTM 300 IU (follitropin alfa injection)
  • Gonal-f® RFF Redi-jectTM 450 IU (follitropin alfa injection)
  • Gonal-f® RFF Redi-jectTM 900 IU (follitropin alfa injection)
  • Gonal-f® Multi-Dose 450 IU (follitropin alfa for injection)
  • Gonal-f® Multi-Dose 1050 IU (follitropin alfa for injection)
  • Gonal-f® RFF 75 IU (follitropin alfa for injection)
  • Cetrotide® .25 mg (cetrorelix acetate for injection)
  • Ovidrel® PreFilled Syringe 250 mcg (choriogonadotropin alfa injection)

Offer not valid for prescriptions that may be covered under private or public insurance or reimbursed under a federal or state healthcare program, including Medicare, Medicaid, or any other similar state healthcare program, including any state medical pharmaceutical assistance program. If you become insured by any private or government insurance you must notify the EMD Serono Compassionate Care program by calling 1-855-541-5926

Card is not transferable and expires one year after program enrollment, unless earlier terminated by EMD Serono

Compassionate Care is not an insurance program.

IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF Gonal-f® RFF Redi-ject™ (follitropin alfa injection)

Indications and Usage: 

  • Induction of ovulation (OI) and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure
  • Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle.
    • Prior to treatment, complete an evaluation of female and male partners to determine infertility diagnosis. Primary ovarian failure and potential pregnancy should be excluded.

Contraindications:

  • hypersensitivity to rhFSH preparations or excipients
  • high levels of FSH indicating primary gonadal failure
  • pregnancy (Pregnancy Category X)
  • uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
  • sex hormone dependent tumors of the reproductive tract and accessory organs
  • tumors of pituitary gland or hypothalamus
  • abnormal uterine bleeding
  • ovarian cyst or enlargement of undetermined origin, not due to polycystic ovary syndrome.

Warnings and Precautions:

  • For use by physicians specializing in fertility treatment or reproductive health and only when appropriate monitoring facilities are available.
  • Gonal-f® RFF Redi-ject™ is a potent gonadotropin.  The lowest effective dose should be used given risk of abnormal ovarian enlargement and Ovarian Hyperstimulation Syndrome (OHSS).  Ultrasound monitoring of ovarian response and/or measurement of estradiol levels are important to minimize risks.  If symptoms of OHSS (severe pelvic or abdominal pain and distension, nausea, vomiting, diarrhea, severe ovarian enlargement, weight gain, dyspnea, oliguria) develop, all gondotropin treatment should be stopped, hCG should be withheld, and intercourse should be prohibited.  OHSS can be severe and requires hospitalization and treatment of fluid and electrolyte imbalances.  OHSS may occur with or without pregnancy.  Women should be assessed for the development of OHSS for at least two weeks after hCG administration.
  • Serious systemic hypersensitivity reactions, including anaphylaxis, have been reported in the postmarketing experience.  Symptoms have included dyspnea, facial edema, pruritis, and urticaria.  If an anaphylactic or other serious allergic reaction occurs, initiate appropriate therapy including supportive measures if cardiovascular instability and/or respiratory compromise occur, and discontinue further use.
  • Thromboembolic events both in association with, and separate from OHSS have been reported in women treated with gonadotropins.  Women with generally recognized risk factors for thrombosis, such as personal or family history, severe obesity, or thrombophilia, may have an increased risk of venous or arterial thromboembolic events, during or following treatment with gonadotropins.  Sequelae of such reactions have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb and rarely in myocardial infarctions.  In rare cases, pulmonary complications and/or thromboembolic reactions have resulted in death.  In women with recognized risk factors, the benefits of OI and ART need to be weighed against the risks.
  • Serious pulmonary conditions (e.g., atelectasis, acute respiratory distress syndrome and exacerbation of asthma) have been reported in women treated with gonadotropins.
  • Ovarian torsion has been reported after treatment with gonadotropins.  This may be related to OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries.  Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion.
  • The couple should be advised of the potential risk of multi-fetal gestation and birth before beginning therapy.  During clinical trials, multiple births occurred in 20% of live births in women receiving therapy for ovulation induction and 35.1 % of live births in women undergoing ART.
  • The incidence of congenital malformations after some ART [specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI.
  • Since women undergoing ART often have tubal abnormalities, the incidence of ectopic pregnancy may be increased
  • The incidence of spontaneous abortion may be increased.  However, causality has not been established.  This may be a factor of the underlying infertility.
  • Both benign and malignant ovarian neoplasms have been infrequently reported; causality has not been established.
  • Both ultrasound and serum estradiol measurement should be used to monitor follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement, and minimizing the risk of the OHSS and multiple gestation.

Adverse Reactions:

The most common adverse reactions (≥5%) in OI include: headache, abdominal pain, and ovarian hyperstimulation.  The most common adverse reactions (≥5%) in ART include: abdominal pain, nausea, abdominal enlargement, headache, and injection site reactions (pain, bruising).

Patient Counseling:

In addition to advising patients about the proper use of treatment, the duration and necessity of monitoring, handling of missed doses, OHSS, and multi-fetal gestation and birth, patients should be advised to review the Patient Information Leaflet which contains risk information, follow the Instructions for Use for the Gonal-f® RFF Redi-ject™, not share the device or reuse needles, and to ask their HCP about questions.

HCP should refer to the full Prescribing Information for full disclosure.

*revised formulation female


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF Gonal-f® (follitropin alfa for injection):

Indication: 

For women, Gonal-f® (follitropin alfa for injection) and Gonal-f® RFF* (follitropin alfa injection) are indicated for 1) the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure and 2) for the development of multiple follicles in the ovulatory patient participating in an ART program. 

Gonal-f® is also indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.

Important Risk Information:  

These products should only be prescribed by physicians specializing in fertility or reproductive health.  Use of Gonal-f® or Gonal-f® RFF by women can result in multiple births.  Gonal-f® and Gonal-f® RFF  are potent gonadotropins capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary complications.  Gonal-f® and Gonal-f® RFF are contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor.  Additionally, Gonal-f® and Gonal-f® RFF  should not be given to women with abnormal bleeding,  presence or enlargement of an ovarian cyst of undetermined origin, or who are pregnant or nursing.  The most common side effects reported in women using Gonal-f® and Gonal-f® RFF include headache, abdominal pain, enlarged abdomen, ovarian cysts, nausea, and upper respiratory infections.  Men using Gonal-f® have commonly reported acne, breast pain and growth, fatigue.  Injection site reactions have been reported.

*revised formulation female


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF OVIDREL® PREFILLED SYRINGE (choriogonadotropin alfa injection):

Ovidrel® PreFilled Syringe (choriogonadotropin alfa for injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as in vitro fertilization (IVF) and embryo transfer.  Ovidrel® PreFilled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure.  Ovidrel®  PreFilled Syringe should only be used by physicians who are thoroughly familiar with infertility problems and their management.  

Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without blood vessel or lung problems. Ovidrel® PreFilled Syringe is contraindicated in women who exhibit prior sensitivity to hCG preparations or their ingredients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Women who are nursing should also not use Ovidrel® PreFilled Syringe The most common side effects in women using Ovidrel® PreFilled Syringe include abdominal pain, injection site reactions, nausea and vomiting.  Reports of multiple births have been associated with Ovidrel® PreFilled Syringe treatment.  


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF CETROTIDE® (cetrorelix acetate for injection):

Cetrotide® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Cetrotide® should be prescribed by physicians who are experienced in fertility treatment.

Cetrotide® is contraindicated in women who exhibit hypersensitivity to cetrorelix acetate, mannitol or medicines similar to Cetrotide®, who exhibit prior hypersensitivity to GnRH or any other GnRH analogs, or who are pregnant, are  breast-feeding or have severe kidney disease. Ovarian Hyperstimulation Syndrome (OHSS), with or without blood vessel or lung problems , can occur with the use of fertility drugs. Mild and short lasting injection reactions like reddening, itching and swelling at the injection sites may occur. Nausea and headache have also been reported.


© 2014 EMD Serono, Inc. and its affiliates.

This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

Gonal-f® Cares about saving patients money.

In addition to great savings on Gonal-f® (follitropin alfa for injection), patients can now save on Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection), and Cetrotide® (cetrorelix acetate for injection).*

                                                  GO Direct to Savings Card

Prescribe Gonal-f®, Ovidrel® PreFilled Syringe, and/or Cetrotide® and provide the patient with a mail-in rebate form. Ask your EMD Serono Sales representative for more details.


Program Details:

  • Self-pay patients, with a valid prescription, can receive a discount, via mail-in rebate, off their out-of-pocket costs for the following EMD Serono products:
    • Gonal-f® (follitropin alfa for injection) ($10)
    • Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) ($10)
    • Cetrotide® (cetrorelix acetate for injection) ($10)
    • Cetrotide® (cetrorelix acetate for injection) ($50)
  • Program is available only for prescriptions filled in the United States
  • Valid submissions must be mailed in and include the original pharmacy receipt and completed GO Direct to Savings rebate form
  • EMD Serono reserves the right to rescind, revoke, terminate or amend the Program, in whole or in part, at any time without notice
  • This Program cannot be combined with special EMD Serono donor pricing
  • If you have any questions, please call 1-866-441-9463
  • This is not an insurance program
  • * Covers the following products:
    • Gonal-f® RFF* Redi-jectTM 300 IU (follitropin alfa injection)
    • Gonal-f® RFF Redi-jectTM 450 IU (follitropin alfa injection)
    • Gonal-f® RFF Redi-jectTM 900 IU (follitropin alfa injection)
    • Gonal-f® Multi-Dose 450 IU (follitropin alfa for injection)
    • Gonal-f® Multi-Dose 1050 IU (follitropin alfa for injection)
    • Gonal-f® RFF 75 IU, single vial pack (follitropin alfa for injection)
    • Gonal-f® RFF 75 IU, 10-vial pack (follitropin alfa for injection)
    • Ovidrel® PreFilled Syringe 250 mcg (choriogonadotropin alfa injection)
    • Cetrotide® 0.25 mg (cetrorelix acetate for injection)
    • Cetrotide® 3 mg (cetrorelix acetate for injection)

IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF Gonal-f® RFF Redi-ject™ (follitropin alfa injection)

Indications and Usage: 

  • Induction of ovulation (OI) and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure
  • Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle.
    • Prior to treatment, complete an evaluation of female and male partners to determine infertility diagnosis. Primary ovarian failure and potential pregnancy should be excluded.

Contraindications:

  • hypersensitivity to rhFSH preparations or excipients
  • high levels of FSH indicating primary gonadal failure
  • pregnancy (Pregnancy Category X)
  • uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
  • sex hormone dependent tumors of the reproductive tract and accessory organs
  • tumors of pituitary gland or hypothalamus
  • abnormal uterine bleeding
  • ovarian cyst or enlargement of undetermined origin, not due to polycystic ovary syndrome.

Warnings and Precautions:

  • For use by physicians specializing in fertility treatment or reproductive health and only when appropriate monitoring facilities are available.
  • Gonal-f® RFF Redi-ject™ is a potent gonadotropin.  The lowest effective dose should be used given risk of abnormal ovarian enlargement and Ovarian Hyperstimulation Syndrome (OHSS).  Ultrasound monitoring of ovarian response and/or measurement of estradiol levels are important to minimize risks.  If symptoms of OHSS (severe pelvic or abdominal pain and distension, nausea, vomiting, diarrhea, severe ovarian enlargement, weight gain, dyspnea, oliguria) develop, all gondotropin treatment should be stopped, hCG should be withheld, and intercourse should be prohibited.  OHSS can be severe and requires hospitalization and treatment of fluid and electrolyte imbalances.  OHSS may occur with or without pregnancy.  Women should be assessed for the development of OHSS for at least two weeks after hCG administration.
  • Serious systemic hypersensitivity reactions, including anaphylaxis, have been reported in the postmarketing experience.  Symptoms have included dyspnea, facial edema, pruritis, and urticaria.  If an anaphylactic or other serious allergic reaction occurs, initiate appropriate therapy including supportive measures if cardiovascular instability and/or respiratory compromise occur, and discontinue further use.
  • Thromboembolic events both in association with, and separate from OHSS have been reported in women treated with gonadotropins.  Women with generally recognized risk factors for thrombosis, such as personal or family history, severe obesity, or thrombophilia, may have an increased risk of venous or arterial thromboembolic events, during or following treatment with gonadotropins.  Sequelae of such reactions have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb and rarely in myocardial infarctions.  In rare cases, pulmonary complications and/or thromboembolic reactions have resulted in death.  In women with recognized risk factors, the benefits of OI and ART need to be weighed against the risks.
  • Serious pulmonary conditions (e.g., atelectasis, acute respiratory distress syndrome and exacerbation of asthma) have been reported in women treated with gonadotropins.
  • Ovarian torsion has been reported after treatment with gonadotropins.  This may be related to OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries.  Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion.
  • The couple should be advised of the potential risk of multi-fetal gestation and birth before beginning therapy.  During clinical trials, multiple births occurred in 20% of live births in women receiving therapy for ovulation induction and 35.1 % of live births in women undergoing ART.
  • The incidence of congenital malformations after some ART [specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI.
  • Since women undergoing ART often have tubal abnormalities, the incidence of ectopic pregnancy may be increased
  • The incidence of spontaneous abortion may be increased.  However, causality has not been established.  This may be a factor of the underlying infertility.
  • Both benign and malignant ovarian neoplasms have been infrequently reported; causality has not been established.
  • Both ultrasound and serum estradiol measurement should be used to monitor follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement, and minimizing the risk of the OHSS and multiple gestation.

Adverse Reactions:

The most common adverse reactions (≥5%) in OI include: headache, abdominal pain, and ovarian hyperstimulation.  The most common adverse reactions (≥5%) in ART include: abdominal pain, nausea, abdominal enlargement, headache, and injection site reactions (pain, bruising).

Patient Counseling:

In addition to advising patients about the proper use of treatment, the duration and necessity of monitoring, handling of missed doses, OHSS, and multi-fetal gestation and birth, patients should be advised to review the Patient Information Leaflet which contains risk information, follow the Instructions for Use for the Gonal-f® RFF Redi-ject™, not share the device or reuse needles, and to ask their HCP about questions.

HCP should refer to the full Prescribing Information for full disclosure.

*revised formulation female


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF Gonal-f® (follitropin alfa for injection):

Indication: 

For women, Gonal-f® (follitropin alfa for injection) and Gonal-f® RFF* (follitropin alfa injection) are indicated for 1) the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure and 2) for the development of multiple follicles in the ovulatory patient participating in an ART program. 

Gonal-f® is also indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.

Important Risk Information:  

These products should only be prescribed by physicians specializing in fertility or reproductive health.  Use of Gonal-f® or Gonal-f® RFF by women can result in multiple births.  Gonal-f® and Gonal-f® RFF  are potent gonadotropins capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary complications.  Gonal-f® and Gonal-f® RFF are contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor.  Additionally, Gonal-f® and Gonal-f® RFF  should not be given to women with abnormal bleeding,  presence or enlargement of an ovarian cyst of undetermined origin, or who are pregnant or nursing.  The most common side effects reported in women using Gonal-f® and Gonal-f® RFF include headache, abdominal pain, enlarged abdomen, ovarian cysts, nausea, and upper respiratory infections.  Men using Gonal-f® have commonly reported acne, breast pain and growth, fatigue.  Injection site reactions have been reported.

*revised formulation female


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF OVIDREL® PREFILLED SYRINGE (choriogonadotropin alfa injection):

Ovidrel® PreFilled Syringe (choriogonadotropin alfa for injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as in vitro fertilization (IVF) and embryo transfer.  Ovidrel® PreFilled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure.  Ovidrel®  PreFilled Syringe should only be used by physicians who are thoroughly familiar with infertility problems and their management.  

Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without blood vessel or lung problems. Ovidrel® PreFilled Syringe is contraindicated in women who exhibit prior sensitivity to hCG preparations or their ingredients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Women who are nursing should also not use Ovidrel® PreFilled Syringe The most common side effects in women using Ovidrel® PreFilled Syringe include abdominal pain, injection site reactions, nausea and vomiting.  Reports of multiple births have been associated with Ovidrel® PreFilled Syringe treatment.  


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF CETROTIDE® (cetrorelix acetate for injection):

Cetrotide® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Cetrotide® should be prescribed by physicians who are experienced in fertility treatment. 

Cetrotide® is contraindicated in women who exhibit hypersensitivity to cetrorelix acetate, mannitol or medicines similar to Cetrotide®, who exhibit prior hypersensitivity to GnRH or any other GnRH analogs, or who are pregnant, are  breast-feeding or have severe kidney disease. Ovarian Hyperstimulation Syndrome (OHSS), with or without blood vessel or lung problems , can occur with the use of fertility drugs. Mild and short lasting injection reactions like reddening, itching and swelling at the injection sites may occur. Nausea and headache have also been reported. 


© 2014 EMD Serono, Inc. and its affiliates.

This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

 


23. Datamonitor, Stakeholder Insight 2008: Infertility, DMHC2418. Q2. 3a. [B]